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TuberculostaticAbstract Tuberculosis (TB) is a disease caused mainly by infection of Mycobacterium tuberculosis
affecting more than ten million people around the world. Despite TB can be treated, the rise of
MDR-TB and XDR-TB cases put the disease in a worrying status. As pyrazinamide-resistant
strains exhibit low or none pyrazinamidase activity, it is proposed that the active form of pyrazin-
amide (PZA) is pyrazinoic acid (POA), although this acid has poor penetration in mycobacteria. In
this work, we present a convenient one-pot synthesis of 2-chloroethyl pyrazinoate, and its activity in
M. tuberculosis H37Rv (ATCC27294) in MIC assay using the MABA technique. The obtained MIC
of the compound was 3.96 g/mL, and discussion about the activity proﬁle of some previously eval-
uated pyrazinoates is also performed.
ª 2013 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Tuberculosis (TB) is a disease caused by the infection with
members of Mycobacterium tuberculosis complex, affecting
more than ten million people worldwide (Barry et al., 1998).
The increase in HIV infection cases was the most importantfactor in the growth in TB prevalence rate. Nowadays, the dis-
ease is getting more worrying status since resistant cases are
rising every day. Despite this, TB resistant cases can be classi-
ﬁed in multidrug resistant TB (MDR-TB, when the resistance
to ﬁrst-line agents is detected, including resistance to isoniazid
or rifampin) and extensively drug-resistant TB (XDR-TB,
when second-line agent resistance is detected) (WHO, 2012;
Zumla et al., 2013).
Although there is an increase in MDR-TB and XDR-TB
cases, the development of new therapeutic options to TB is
stagnant. Since the discovery of rifampin, in 1965, no other
important speciﬁc antimycobacterial drug has been introduced
in therapeutics against susceptible TB. However, bedaquiline
(a diarylquinoline) was recently introduced in the treatment
of MDR-TB (Sirturo, 2013). Nevertheless, several research
groups worldwide are involved in obtaining new chemical enti-
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Group on New TB Drugs, 2013; Zumla et al., 2013).
Mycobacteria are slow-growing bacilli that possess an
external cell wall composed by highly lipophilic fatty acids,
the mycolic acids (Barry et al., 1998; Brennan and Nikaido,
1995; Zumla et al., 2013). Because of this unusual characteris-
tic, antimycobacterial agents might have good penetration
through this barrier. In fact, this is one of the most important
roles to be fulﬁlled by antimycobacterial agents. Many of the
anti-TB compounds have difﬁculties to cross the mycobacterial
cell wall (Liu et al., 1996).
Pyrazinamide (PZA) was discovered during investigations
of analogs of nicotinamide (Kushner et al., 1952). It is consid-
ered a bioisostere of nicotinamide. PZA is valuable in TB con-
trol, because it becomes active in acid conditions and may kill
bacteria inside the granuloma, while other drugs lose their
activity under these conditions, but some mycobacterial strains
are naturally resistant to PZA. It is proposed that PZA inter-
fere with the energetics and functions of the membrane (Zhang
et al., 2003). However, the entire mechanism of action of PZA
is unknown. It was veriﬁed that the conversion of PZA to pyr-
azinoic acid (POA) (Fig. 1) could play the main role in its ac-
tion, because PZA-resistant strains do not express the enzyme
responsible for the conversion to POA (named as pyrazinami-
dase, PZAse) (Bergmann et al., 1996; Cynamon et al., 1992,
1995; Konno et al., 1967). POA itself is poorly active in anti-
mycobacterial tests, while it cannot pass through mycobacte-
rial cell walls. This inactivity is due to its low lipophilicity
and highly ionized state in physiological pHs. Thus, the pro-
drug approach to direct POA inside mycobacteria is suitable
to increase its activity, including into PZA-resistant mycobac-
terial strains, since it can change its physicochemical character-
istics (Cynamon et al., 1992, 1995).
Cynamon et al. (1992, 1995) synthesized a series of POA es-
ters and derivatives as prodrugs, exhibiting good in vitro anti-
mycobacterial activity against several mycobacterial strains,
including the PZA-resistant strain of M. tuberculosis ATCC
35828. In an earlier work (Bergmann et al., 1996), they pro-
posed a classical quantitative structure–activity relationship
(QSAR) model (N= 47, r2 = 0.56, s= 0.54; and, N= 34,
r2 = 0.57, s= 0.54) to those derivatives and several mycobac-
terial strains using the following independent variables: Ham-
met’s r, n-octanol/water partition coefﬁcient (logP), the time
of ester hydrolysis in serum (log t), and Charlton’s steric sub-
stituent constant (). More recently, our group presented a mul-
tivariate QSAR model of these compounds (N= 32,
r2 = 0.68, q2 = 0.59, LOF = 0.25, LSE = 0.19, outliers = 0),
obtaining the Balaban index J, C logP, the stretching energy
contribution (Estretch), the van der Waals molecular surface
area (SvdW) and the dipole moment (l) as important descrip-
tors (Fernandes et al., 2010). The validated model showed that
lipophilicity and molecular size are the most important factors
that determine the activity of these esters.PZAase
PZA POA
Figure 1 Activation of PZA into POA.Although pyrazinoate esters are important alternatives to
be considered in resistant TB strains, it did not achieve the
therapeutics yet. Clinical studies were not performed with it,
and economical aspects should be considered as a factor in
its indifference. Considering these, the aim of this study is to
present a convenient one-pot synthesis of a POA prodrug,
and also its antimycobacterial activity against M. tuberculosis
H37Rv (ATCC 27294).
2. Material and methods
Chemical compounds were commercially acquired in adequate
purity and used without previous treatment. Spectrometric
analysis in infrared (IR) was performed in Bomem FTIR
Michelson series equipment, between wave numbers 4000
and 400 cm1, using NaCl plates as support. NMR analyses
were performed in Bruker DPX-300 equipment, operating at
300 for 1H and 75 MHz for 13C. Chemical shifts (d= ppm)
were measured using tetramethylsilane (TMS) as reference.
Elemental analysis was performed in Perkin–Elmer CHN
2400 equipment.
2.1. Synthetic procedure
In approximately 20 mL of 2-chloroethanol, 5 mmol (0.620 g)
of POA was added under vigorous stirring. The solution was
kept in reﬂux, when 5.5 mmol (0.650 g – 10% excess) of thionyl
chloride was added. The solution was maintained under heat-
ing and stirring for 3 h. The reaction mixture was then evapo-
rated, and the remaining oily liquid was dried under vacuum.
After this, 10 mL of diethyl ether was added, and the organic
solution was washed with 15 mL of saturated NaHCO3 and
brine. The organic phase was dried with anhydrous Na2SO4
and evaporated. The reaction was monitored by TLC, using
chloroform:methanol (8:2) as eluent. The product was ob-
tained as a yellowish oily liquid. Yield: 0.84 g (90%). IR
(NaCl): mmax 1737.38 cm
1 (C‚O). 1H NMR: (300 MHz,
CDCl3, TMS, d= ppm) 9.34 (s, ArH7, 1H); 8.87 (s, ArH4,
1H); 8.82 (s, ArH5, 1H); 4.75 (t, OCH2, J= 5.7 Hz, 2H);
3.95 (t, CH2Cl, J= 5.7 Hz, 2H).
13C NMR (75 MHz, CDCl3,
TMS, d= ppm) 163.54 (C1); 147.96 (C5); 146.44 (C7); 144.60
(C4); 143.05 (C2); 65.48 (OCH2); 41.18 (CH2Cl). Elemental
analysis calculated: C = 45.0%; H = 3.8%; N = 15.0%;
Cl = 19.0%. Found: C = 44.8%; H= 3.7%; N = 14.6%;
Cl = 18.9%.
2.2. Determination of antimycobacterial activity
The microplate Alamar blue assay (MABA) was used to mea-
sure the minimal inhibitory concentration (MIC) for the tested
compounds (minimum concentration necessary to inhibit 90%
growth of M. tuberculosis H37Rv ATCC 27294) (Franzblau
et al., 1998). In a sterile 96-well microplate was added 200
lL of distilled water in each well of the outer-perimeter, to
avoid water evaporation during incubation. The test
compounds (POA, 2-chloroethyl pyrazinoate and ciproﬂoxa-
cin) were diluted in DMSO to obtain solutions, and thereafter,
were diluted in Middlebrook 7H9 to obtain variable concentra-
tions of the compounds, with starting concentration of 250 g/
mL. The M. tuberculosis H37Rv (ATCC 27294) strain was
cultivated in 7H9 broth at 37 C until reaching the turbidity
SOCl2
Figure 2 Preparation of 2-chloroethyl pyrazinoate.
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times, and then 100 lL of bacterial suspension was inoculated
in each well containing the compound solutions. The micro-
plates were sealed with paraﬁlm and incubated at 37 C for
6 days, when Alamar Blue solution was added to the control
wells containing the mycobacterial strain. The plates were rein-
cubated for 24 h, when the reading was performed. The blue
color in the wells was deﬁned as negative bacterial growth,
while the pink color development was deﬁned as positive
growth. The microplates showing wells with violet color were
reincubated for 24 h, and if color change to pink was detected,
the growth was considered positive. If the color was main-
tained, the growth is negative.
2.3. LogP calculation
The logP of POA and of the esters 2-chloroethyl, allyl, n-pro-
pyl, isobutyl, tetradecyl and hexadecyl pyrazinoates were cal-
culated using the freeware software Marvin 5.5 (Chemaxon,
2011). The structures were built up in the program prior to
the calculation in its neutral form. The logP value was calcu-
lated using the methodology described by Viswanadhan et al.
(1989). These calculations are fragment-based and are imple-
mented in the software. The program MarvinSketch allows
the user to weigh the calculation, extended by the methods
of Klopman et al. (1994) and PhysProp database (Syracuse Re-
search Corporation, 1994), being 1 for all of them. The stipu-
lated Na+, K+ and Cl concentrations used in the
calculations were 0.1 M.
3. Results and discussion
Among the alternatives explored to achieve new antimycobac-
terial agents is the prodrug approach. Prodrugs are transport
forms that can solve several problems regarding well-known
drugs (Chung et al., 2008). POA prodrugs can be considered
an alternative to obtain antimycobacterial molecules. Despite
POA being considered the active form of PZA, it cannot cross
the hydrophobic cell wall of mycobacteria, due to its high
hydrophilic and ionizable characteristics. Cynamon et al.,
1992; proposed the esteriﬁcation of POA to obtain more lipo-
philic compounds of the active agent, able to cross the cell
wall. Several compounds exhibiting activity were synthesized,
5-chloropyrazinoates and 5-methylpyrazinoates being the most
active analogs (Cynamon et al., 1992, 1995). Other groups also
evaluated some POA esters, with good activity results (Seitz
et al., 2002).
Cynamon et al. (1992) presented the synthesis of POA es-
ters through the alcoholysis reaction of pyrazinoyl chloride
in two steps. The pyrazinoyl chloride was prepared using ex-
cess of thionyl chloride (15 mL to 30 mmol of POA), isolated,
and then the acyl chloride was used in the reaction with the
corresponding alcohol in dichloromethane with the presence
of pyridine as base to neutralize the HCl formed in situ. Using
this procedure, the authors obtained 74% yield to the pyrazi-
noyl chloride preparation, and variable yields ranging from
24% to 79% to the ester syntheses. Speciﬁcally to the synthesis
of 2-chloroethyl pyrazinoate, the total obtained yield was
42%. In a following work (Cynamon et al., 1995), the authors
reported again the pyrazinoate syntheses by the same method-
ology, obtaining yields of 70–80% to the pyrazinoyl chloride,and in the alcoholysis step, the yields were 60–90%. After
two steps, the effective yields were around 50%.
In a latter work, Simo˜es et al. (2009) reported the synthesis
of higher chain pyrazinoates than that previously reported by
Cynamon and colleagues. The synthetic procedure was similar
to earlier reports, however the pyrazinoyl chloride was ob-
tained using thionyl chloride as solvent (25 mL to 26.5 mmol
of POA), and the alcoholysis step was done using triethyl-
amine as base. The ﬁnal yields to the preparation of the esters
were 42–46%.
In addition to this synthetic route, there are in the literature
different procedures to obtain the pyrazinoate esters. Seitz
et al. (2002) reported the esteriﬁcation of POA by the reaction
with dicyclohexylcarbodiimide (DCC) in the presence of N,N-
dimethylaminopyridine (DMAP) as catalyst. This method is
widely used in ester synthesis, but the yields are frequently var-
iable and it gives byproducts, such as dicyclohexylurea (DCU)
and N-acylureas, very hard to remove (March, 1992). In a pre-
vious work, our group presented the synthesis of POA esters
by the reaction between alkyl halides and carboxylates,
through nucleophilic substitution (Fernandes and Felli,
2009). With this method, were obtained two pyrazinoate esters,
the ethyl and n-hexyl pyrazinoates, with 62–76% yields, higher
than that presented by Cynamon et al. (1992), but with the
advantage to be done in a one-pot reaction. The carboxylates
were generated in situ using DBU or triethylamine.
In the present work, is reported the synthesis of POA esters
in a one-pot step, through the reaction with thionyl chloride
and the corresponding alcohol, without any additional base
(Fig. 2). This is possible because the pyrazine nitrogen can
act as a base to quench the formed HCl, dispensing the use
of triethylamine or pyridine. In fact, the pyrazine ring can
act as pyridine, since they have the same characteristic.
It was observed that POA exhibit good solubility in 2-chlo-
roethanol. This ﬁnding became possible using this reagent as
the solvent of the reaction, improving the yield. Moreover,
the 2-chloroethanol can easily be removed by evaporation
due its low boiling point. The yield obtained with this method-
ology (90%) is higher than that obtained by Cynamon et al.
(1992, 1995). The characterization data of the product show
that the desired 2-chloroethyl pyrazinoate was obtained and
isolated with good purity. Thus, the results indicate the present
methodology is more adequate to synthesize pyrazinoate
esters.
The results obtained in the MIC assay showed a signiﬁcant
increase in the POA activity after esteriﬁcation. The obtained
MIC value (3.96 g/mL) is comparable to the MIC of ciproﬂox-
acin, a second-line agent with high activity, and used in the
treatment of MDR-TB and other mycobacteriosis (Table 1)
and better than PZA (reported MIC 50–100 g/mL). This in-
crease was predicted, however there were no MIC data of this
compound against M. tuberculosis H37Rv.
Kushner et al. (1952) evaluated the activity of thiopyrazino-
ates and veriﬁed that some of these compounds, mainly the
isopropyl-thiopyrazinoate, showed antimycobacterial activity.
Table 1 MICs results for POA, cip-
roﬂoxacin and 2-chloroethyl pyrazino-
ate using the Alamar Blue (MABA)
technique.
Compounds MIC (g/mL)
POA 15.62
Ciproﬂoxacin 3.96
2-Chloroethyl pyrazinoate 3.96
Table 2 LogP values for the selected compounds.
Compounds log P MIC (g/mL)
POA 0.42 15.62
2-Chloroethyl pyrazinoate 0.39 3.96
Allyl pyrazinoate 0.46 3.25a
n-Propyl pyrazinoate 0.61 3.25a
Isobutyl pyrazinoate 0.97 2b
n-Tetradecyl pyrazinoate 5.50 10c
n-Hexadecyl pyrazinoate 6.39 40c
a Obtained from Ref. Franzblau et al. (1998).
b Obtained from Ref. Klopman et al. (1994).
c Obtained from Ref. Seitz et al., (2002).
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ylmercaptane, and not to POA. The ﬁrst report that POA es-
ters could present antimycobacterial activity was done by
Solomons and Spoerri (1953), in a work searching for local
anesthetic activity of POA and 2,3-pyrazinedioic acid.
It is noted that PZA present better activity in vitro in acidic
pH (Cynamon et al., 1992; Seitz et al., 2002). It is veriﬁed that
the activity increases as pH decreases, being the optimum
activity reached when the medium pH is approximately 5.8
(Cynamon et al., 1992, 1995).
In the MIC assay performed in this work, we obtained
activity of 3.96 g/mL to the 2-chloroethyl pyrazinoate in pH
6.6 against M. tuberculosis H37Rv. It is possible to infer that
2-chloroethyl pyrazinoate may show better activity in pH
5.8, and comparing with other compounds reported in the lit-
erature, it is considered a highly active compound (Fernandes
et al., 2010). It is observed a 2 to 8-fold increase in the activity
of POA esters when the pH is lowered from 6.6 to 5.8 (Cyna-
mon et al., 1992). Thus, it can be estimated the activity of 2-
chloroethyl pyrazinoate can be even lower.
In order to evaluate the potential biological activity of non-
tested compounds, some pyrazinoates previously synthesized
by us [18] had their activity predicted by our previously pub-
lished QSAR model (Fernandes et al., 2010). The predicted
pMIC value to 2-chloroethyl pyrazinoate was 2.32, but in a
different protocol from that presented now. In this work, this
compound had its activity evaluated against the strain M.
tuberculosis H37Rv ATCC 27294, using the Alamar Blue
(MABA) methodology [20], and its experimental pMIC was
1.67 (equivalent to 3.96 g/ml).
It is reported in the literature a MIC value of 6.25 g/ml to 2-
chloroethyl pyrazinoate in pH 5.8 against M. bovis ATCC
27289, and to M. tuberculosis BUR (Cynamon et al., 1992).2-chloroethyl pyrazinoa
allyl pyrazinoate n-propyl pyrazinoa
n-tetradecyl pyrazinoate
Figure 3 POIt is important to highlight theM. bovis is considered naturally
resistant to PZA. Thus, the 2-chloroethyl pyrazinoate can be
considered active in some resistant strains of mycobacteria.
In this previous report, the authors did not perform the MIC
assay of this compound in M. tuberculosis H37Rv. The com-
pounds that exhibited better activity were the allyl and the n-
propyl pyrazinoates, with MIC values lower than 3.25 g/mL
(Fig. 3). In the latter work, the authors obtained MIC values
lower than 2 g/mL to four compounds, isobutyl, n-decyl, n-
pentadecyl and benzyl pyrazinoates (Cynamon et al., 1995).
More recently, Simo˜es et al. (2009) presented a work
reporting the synthesis, antimycobacterial activity and enzy-
matic stability of POA esters and the equivalent amides. The
authors observed that the amides were very stable, even in
M. smegmatis homogenates, concluding that they will not be
activated inside mycobacteria. MIC assays corroborate with
this ﬁnding, showing MIC values higher than 800 g/mL to
these amides. However, the long-chain esters of POA (dodecyl,
tetradecyl and hexadecyl esters) showed MIC values ranging
from 10 to 40 g/mL (Fig. 3).
Analyzing these previous works, it is possible verify a
strong positive relationship of the side chain of the esters
(and also its lipophilicity) with the antimycobacterial activity.
The higher the side chain, the higher is the lipophilicity and
higher the antimycobacterial activity. Regarding this, in coun-
terpart, it is possible to verify that lower chain derivatives
show similar activity than the higher chain derivatives (Ta-
ble 2). This can be explained by the excessive lipophilicity,te
te isobutyl pyrazinoate
n-hexadecyl pyrazinoate
A esters.
380 Joa˜o Paulo-dos Santos Fernandes et al.which reduces the water solubility, becoming more difﬁcult the
diffusion through the bacterial cell wall, and compromising the
usefulness of these compounds as future drugs. Thus, mole-
cules with low logP and adequate MIC should be considered
as more promising. Considering this, the 2-chloroethyl pyraz-
inoate can be deﬁned as a promising compound, since its logP
is lower than derivatives with similar activity.
It is concluded that the 2-chloroethyl pyrazinoate can be
synthesized by an efﬁcient one-pot procedure, with high yield
and adequate purity. Moreover, it can be considered a prom-
ising alternative as prodrug with activity in PZA resistant
strains.Acknowledgements
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